

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2022

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria. Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £45.

DISEASE / DISORDER	Price (£)	Routine TAT (Calendar days)	Gene(s) or locus	Description of test <i>(including reference intervals/ clinical decision values where applicable)</i>	Category
<b>CYTOGENETIC TESTS</b>					
<u>Fetal loss referrals:</u>					
Microarray analysis <b>R22.2, R318.2</b>	435	42	Genome-wide CNVs	Analysis, interpreting and reporting	
DNA storage	45	N/A			
<u>Postnatal cytogenetic referrals:</u>					
Common aneuploidy testing <b>R26.1</b>	205	3 <sup>1</sup> /42		QF PCR	
Microarray (multiple indications)	435	42		Analysis, interpreting and reporting	
Targeted follow up testing	205	42		Microarray analysis or FISH	
Karyotype <b>R297.1</b>	295	42		G banding	
FISH	295	42		FISH	
		<sup>1</sup> urgent neonates			
<b>MOLECULAR GENETIC TESTS</b>					
Albinism or congenital nystagmus <b>R39</b>	885	84	23-gene panel	Next-generation sequencing	NGS service
<i>TYR</i> and <i>OCA2</i> dosage analysis*	130	42	<i>TYR, OCA2</i>	MLPA	Targeted mutation test
Albright hereditary osteodystrophy, pseudohypoparathyroidism, pseudopseudohypoparathyroidism, acrodysostosis and osteoma cutis					Imprinting analysis
Methylation testing <b>R293.2</b>	245	42	<i>GNAS</i>	MS-MLPA	
UPD(20) follow-up <b>R263</b>	365	42	No specific gene	Microsatellite analysis	
<i>GNAS</i> sequencing <b>R293.1</b>	470	42	<i>GNAS</i>	NGS + Sanger sequencing	NGS service

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2022

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria.

Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £45.

Alpha 1 - antitrypsin deficiency <b>R191</b>	245	42	<i>SERPINA1</i>	Two common mutations (S & Z)	Targeted mutation test
Angelman syndrome <b>R47</b> Chromosome 15 abnormalities	245	42	<i>SNURF:TSS-DMR</i>	MS-MLPA	Imprinting analysis
UPD(15) follow-up <b>R263</b>	365	42	No specific gene	Microsatellite analysis	
Aortopathy panel	See Thoracic aortic aneurysm or dissection				
Beckwith-Wiedemann syndrome <b>R49</b> ; isolated hemihypertrophy or macroglossia <b>R50</b> Chromosome 11 abnormalities (ICR1 and ICR2)	245	42	<i>H19-IGF2:IG-DMR, KCNQ10T1:TSS-DMR</i>	MS-MLPA	Imprinting analysis
UPD(11) follow-up <b>R263</b>	365	42	11p15.5	Microsatellite analysis	
<i>CDKN1C</i> sequencing <b>R49.3</b>	370	42	<i>CDKN1C</i>	Sanger sequencing	Single gene screen
Blepharophimosis, ptosis and epicanthus inversus (BPES) <b>R43</b>	485	42	<i>FOXL2</i>	Full mutation screen + MLPA + fragment analysis	Single gene screen
Breast/ovarian cancer	See Inherited breast cancer and ovarian cancer				
Ovarian cancer	See Inherited ovarian cancer (without breast cancer)				
Chronic myeloid leukaemia (CML)	See Oncology genetics page on our website				
Chronic lymphoblastic leukaemia (CLL)	See Oncology genetics page on our website				
Confirmation of variants (e.g. from research studies or non-accredited sources)	130	42	<i>Please note: these may be sent to other specialist laboratories for testing as appropriate or where specified by the National Genomic Test Directory; prices for outsourced tests may differ from those quoted here.</i>		Targeted mutation test
Cowden syndrome	See <i>PTEN</i> hamartoma tumour syndrome				
Cystic fibrosis Routine diagnostic or carrier testing <b>R184.1, R185.1</b>	245	42	<i>CFTR</i>	50 most common UK mutations	Targeted mutation test
Urgent carrier testing <b>R185.1</b>	245	14	<i>CFTR</i>	50 most common UK mutations	

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2022

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria. Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £45.

Newborn screen from blood spots <b>R253</b>	130	4 working days	<i>CFTR</i>	4 most common UK mutations	
Factor V Leiden and Prothrombin mutations*	245	42	<i>F5, F2</i>	NGS genotyping	Targeted mutation test
Familial testing for known variants Predictive testing <b>R242</b> Carrier testing <b>R244</b> Parental/segregation testing <b>R375</b>	245	14 42 42	<i>Please note: these may be sent to other specialist laboratories for testing as appropriate or where specified by the National Genomic Test Directory; prices for outsourced tests may differ from those quoted here.</i>		Targeted mutation test
Haematological malignancies	See Oncology genetics page on our website				
Haemochromatosis	See Iron overload – hereditary haemochromatosis testing				
Hypogonadotropic hypogonadism <b>R148</b> 14-gene panel	885	84	14-gene panel	Next-generation sequencing	NGS service
Inherited breast cancer and ovarian cancer <b>R208</b> Routine Urgent (including mainstream referrals)	775	42 21	<i>BRCA1, BRCA2, PALB2</i>	Next-generation sequencing + MLPA for <i>BRCA1</i> and <i>BRCA2</i>	NGS service
Inherited ovarian cancer (without breast cancer) <b>R207</b>	885	42	8-gene panel	Next-generation sequencing + MLPA for <i>BRCA1</i> and <i>BRCA2</i>	NGS service
Iron overload – hereditary haemochromatosis testing <b>R95</b>	245	42	<i>HFE</i>	Two common mutations	Targeted mutation test
Kagami-Ogata syndrome <b>R268</b> Methylation abnormalities	245	42	<i>MEG3:TSS-DMR</i>	Methylation-sensitive MLPA	Imprinting analysis
Paternal UPD(14) follow-up <b>R263</b>	365	42	No specific gene	Microsatellite analysis	
Kallmann syndrome	See Hypogonadotropic hypogonadism				
Marfan syndrome	See Thoracic aortic aneurysm or dissection				
Multi-locus imprinting disorder <b>R417.1</b>	245	42	No specific gene	Methylation-sensitive MLPA for chromosomes 6, 7, 11, 14, 15, 19 and 20	Imprinting analysis
Myeloproliferative neoplasia (MPN)	See Oncology genetics page of our website				

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2022

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria. Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £45.

Neurofibromatosis type 1 (NF1) <b>R222</b> (including Legius syndrome*)	775	42	<i>NF1, SPRED1</i>	Next-generation sequencing + MLPA for <i>NF1</i>	NGS service
Oculopharyngeal muscular dystrophy (OPMD) <b>R75</b>	130	42	<i>PABPN1</i>	Fluorescent PCR (Normal: 10 repeats; Pathogenic: 11-17 repeats)	Repeat expansion test
Prader-Willi syndrome <b>R48</b> Chromosome 15 abnormalities	245	42	<i>SNURF:TSS-DMR</i>	MS-MLPA	Imprinting analysis
UPD(15) follow-up <b>R263</b>	365	42	No specific gene	Microsatellite analysis	
Prenatal testing for known pathogenic variants* (to include maternal cell contamination testing <b>R321</b> where a maternal sample is available)	375	3	<i>Please note: these may be sent to other specialist laboratories for testing as appropriate or where specified by the National Genomic Test Directory; prices for outsourced tests may differ from those quoted here.</i>		Targeted mutation test
Primary ciliary dyskinesia (PCD)	See Respiratory ciliopathies				
Pseudohypoparathyroidism (PHP)	See Albright hereditary osteodystrophy				
<i>PTEN</i> hamartoma tumour syndrome <b>R213</b>	485	42	<i>PTEN</i>	Mutation screening by NGS + MLPA	NGS service
Respiratory ciliopathies including non-CF bronchiectasis <b>R189</b>	1050	84	46-gene panel	Next-generation sequencing	NGS service
RNA studies (investigating the effect of sequence variants on splicing) <b>R296</b>	615	42	No specific gene	Analysis of DNA variants for splicing abnormalities	Specialised testing
Russell-Silver syndrome	See Silver-Russell syndrome				
Silver-Russell syndrome (Growth failure in early childhood) <b>R147.2</b> Chromosome 11 abnormalities (ICR1 only) and UPD(7) analysis	245	42	<i>H19-IGF2:IG-DMR,</i> <i>GRB10:alt-TSS-DMR,</i> <i>MEST:alt-TSS-DMR</i>	MS-MLPA	Imprinting analysis
UPD(11) follow-up <b>R263</b>	365	42	No specific gene	Microsatellite analysis	
Thoracic aortic aneurysm or dissection (TAAD) <b>R125</b>	1050	84	32-gene panel	Next-generation sequencing + MLPA for <i>FBN1</i> only	NGS service

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2022

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria. Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £45.

Temple syndrome <b>R267</b> Methylation abnormalities	245	42	<i>MEG3</i> :TSS-DMR	MS-MLPA	Imprinting analysis
Maternal UPD(14) follow-up <b>R263</b>	365	42	No specific gene	Microsatellite analysis	
Transient neonatal diabetes mellitus (TNDM) (6q24-related neonatal diabetes, <b>R143.3</b> )	245	42	<i>PLAGL1</i> :alt-TSS-DMR	6q24 methylation, UPD and dosage analysis by MLPA	Imprinting analysis
UPD(6) follow-up <b>R263</b>	365	42	No specific gene	Microsatellite analysis	
Uniparental disomy confirmation <b>R263</b> (where no prior imprinting analysis at WRGL)	600	42	No specific gene	Microsatellite analysis	UPD confirmation
X-inactivation studies <b>R111</b>	245	42	No specific gene	Methylation analysis by restriction enzyme digestion ( <i>Random = &lt;80:20 ratio; skewed = &gt;91:9 ratio</i> ).	Specialised testing